Current status of therapy of solid tumors Journal Article


Authors: Jhanwar, Y. S.; Divgi, C.
Article Title: Current status of therapy of solid tumors
Abstract: The recent approval of 2 radiolabeled antibodies against cluster designation 20-positive lymphoma has led to a resurgence of interest in radioimmunotherapy. As was the case with chemotherapy development, progress has been most marked in the hematologic neoplasms, both in myeloablative and in nonmyeloablative therapeutic strategies. Success in the radioimmunotherapy of solid tumors has lagged because of the immunogenicity of murine proteins and the relatively slow clearance of humanized intact immunoglobulins. Genetic engineering has enabled the development of a variety of antigen-binding constructs of various sizes and immunobiologic characteristics. Developments in radiochemistry as well as production of an increasing number of radionuclides with therapeutic potential or optimal imaging characteristics have spurred tailored therapeutic strategies that include dosimetry and considerations of tumor burden. Such progress has generated pivotal studies that will establish the radiobiologic paradigms for successful radioimmunotherapy of solid tumors. This review will describe seminal studies that have paved the way to an understanding of radioimmunotherapy in solid tumors. Finally, the authors' views of the future of this promising cancer therapy will be presented.
Keywords: unclassified drug; clinical trial; review; advanced cancer; nonhuman; solid tumor; drug targeting; ibritumomab tiuxetan; methodology; radiopharmaceuticals; clinical practice; neoplasm; neoplasms; physician's practice patterns; prostate specific antigen; animal; animals; ovary cancer; carcinoembryonic antigen; colonic neoplasms; practice guideline; monoclonal antibody; drug delivery systems; membrane antigen; prostate specific membrane antigen; antibodies, monoclonal; nonhodgkin lymphoma; iodine 131; drug distribution; genetic engineering; lymphoma, non-hodgkin; colon tumor; radioactivity; radiopharmaceutical agent; drug clearance; thyroid cancer; drug absorption; radioisotope; drug half life; antigen binding; radioimmunotherapy; radioisotopes; gallium 67; drug delivery system; solid tumors; radiochemistry; myeloid leukemia; yttrium 90; actinium 225; astatine 211; bismuth 213; practice guidelines; rhenium 188; lutetium 177; radionuclides; rhenium 186; copper 67; antigen-binding construct; tag 72 antigen
Journal Title: Journal of Nuclear Medicine
Volume: 46
Issue: 1 Suppl.
ISSN: 0161-5505
Publisher: Society of Nuclear Medicine  
Date Published: 2005-01-01
Start Page: 141S
End Page: 150S
Language: English
PUBMED: 15653662
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 35" - "Export Date: 24 October 2012" - "CODEN: JNMEA" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Chaitanya Divgi
    163 Divgi
Related MSK Work